Shares of health-care companies fell after President Donald Trump raised the issue of drug prices. During a press conference with Senate Majority Leader Mitch McConnell, Mr. Trump expressed his desire to address "out of control prescription-drug costs," The Wall Street Journal reported. Allergan declined after a judge invalidated the patent on the drug maker's second best-seller, the Restasis eye drug, opening the door for generic competition from Teva Pharmaceutical and others.
-Rob Curran, firstname.lastname@example.org
Continue Reading Below
(END) Dow Jones Newswires
October 16, 2017 16:44 ET (20:44 GMT)